Eli Lilly and Company (LLY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Sales | 19,292,000 | 17,600,800 | 15,557,700 | 12,728,500 | 13,533,100 |
| Cost of Goods | 3,371,700 | 3,008,300 | 2,447,800 | 2,224,200 | 2,403,500 |
| Gross Profit | 15,920,300 | 14,592,500 | 13,109,900 | 10,504,300 | 11,129,600 |
| Operating Expenses | 7,546,600 | 7,227,300 | 6,243,700 | 6,809,399 | 6,416,301 |
| Operating Income | 8,374,399 | 7,365,500 | 6,867,000 | 3,695,101 | 4,713,801 |
| Other Income | -108,299 | -133,100 | -90,600 | -239,001 | 324,498 |
| Pre-tax Income | 8,266,100 | 7,232,400 | 6,776,400 | 3,456,100 | 5,038,299 |
| Income Tax | 1,628,400 | 1,649,900 | 1,115,900 | 696,800 | 628,500 |
| Net Income Continuous | 6,637,700 | 5,582,500 | 5,660,500 | 2,759,300 | 4,409,800 |
| Net Income | $6,637,700 | $5,582,500 | $5,660,500 | $2,759,300 | $4,409,800 |
| EPS Basic Total Ops | 7.41 | 6.22 | 6.30 | 3.07 | 4.90 |
| EPS Basic Continuous Ops | 7.40 | 6.22 | 6.30 | 3.07 | 4.90 |
| EPS Diluted Total Ops | 7.39 | 6.21 | 6.29 | 3.06 | 4.88 |
| EPS Diluted Continuous Ops | 7.39 | 6.21 | 6.29 | 3.06 | 4.88 |
| EPS Diluted Before Non-Recurring Items | 7.54 | 7.02 | 6.31 | 3.34 | 5.32 |
| EBITDA(a) | $8,960,100 | $7,835,500 | $7,345,500 | $4,157,900 | $5,198,997 |